Term,Overlap,P.value,Adjusted.P.value,Old.P.value,Old.Adjusted.P.value,Odds.Ratio,Combined.Score,Genes
Validated transcriptional targets of AP1 family members Fra1 and Fra2 Homo sapiens 76d028a7-6196-11e5-8ac5-06603eb7f303,2/35,8.91505192832842e-06,0.000124810726996598,0,0,1209.93939393939,14068.896359724,PLAU;CCL2
AP-1 transcription factor network Homo sapiens 3ce2f9c5-6189-11e5-8ac5-06603eb7f303,2/69,3.51113915014889e-05,0.000245779740510423,0,0,594.925373134328,6102.14059024941,PLAU;CCL2
Proteins Involved in Glioma,3/290,3.01738014815311e-06,0.000276095361914298,0,0,59130,751608.620425921,CYP27B1;PLAU;CCL2
RAGE/AGER and S100 Proteins in Cardiovascular Injury,2/30,6.5187917475775e-06,0.000276095361914298,0,0,1426.35714285714,17031.8760580581,PLAU;CCL2
ROS in Triggering Vascular Inflammation,2/32,7.43243614212135e-06,0.000276095361914298,0,0,1331.13333333333,15720.2279199713,PLAU;CCL2
Tumor Infiltrating Macrophages in Cancer Progression and Immune Escape,2/36,9.4391576722837e-06,0.000276095361914298,0,0,1174.29411764706,13587.3389651387,PLAU;CCL2
IL1B Expression Targets -> Nociception,2/47,1.61905438328707e-05,0.000378858725689175,0,0,886.755555555556,9781.87431154951,PLAU;CCL2
Hepatic Stellate Cells in non-Alcoholic Fatty Liver Disease,2/55,2.22355362508991e-05,0.000433592956892532,0,0,752.603773584906,8063.26047108095,PLAU;CCL2
Plasmin Effects in Inflammation,2/68,3.4094799344218e-05,0.000569870217610502,0,0,603.969696969697,6212.65317306081,PLAU;CCL2
FRA pathway,2/37,9.97821116697531e-06,0.000738387626356173,0,0,1140.68571428571,13135.1177402448,PLAU;CCL2
Proteins Involved in HIV Type 1 Infection,2/88,5.72556299926871e-05,0.000778687642149946,0,0,463.046511627907,4523.03118534928,PLAU;CCL2
Mast-Cells De Novo Synthesized Mediators via IgE Independent Signaling,2/90,5.98990493961497e-05,0.000778687642149946,0,0,452.477272727273,4399.36861621238,PLAU;CCL2
Lung fibrosis WP3624,2/63,2.92353668765243e-05,0.000780974659247056,0,0,653.639344262295,6824.08063393686,PLAU;CCL2
Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341,2/71,3.71892694879551e-05,0.000780974659247056,0,0,577.623188405797,5891.46210311105,CYP27B1;CCL2
Proteins Involved in Diabetes Mellitus Type 1,2/97,6.96192473164352e-05,0.000814545193602291,0,0,418.989473684211,4010.76395219608,CYP27B1;CCL2
AP-1 transcription factor network,2/70,3.61428820475583e-05,0.00133728663575966,0,0,586.147058823529,5995.1300122651,PLAU;CCL2
Proteins Involved in Prostate Cancer,2/138,0.000141153874297156,0.00150136393570611,0,0,292.073529411765,2589.42459378401,PLAU;CCL2
Proteins Involved in Pulmonary Hypertension,2/165,0.000201850280328247,0.00196804023320041,0,0,243.361963190184,2070.51976736193,PLAU;CCL2
TNF-alpha Signaling via NF-kB,2/200,0.000296535132839628,0.0020757459298774,0,0,199.989898989899,1624.58691694667,PLAU;CCL2
Proteins Involved in Amyotrophic Lateral Sclerosis,2/181,0.000242895970167847,0.00218606373151062,0,0,221.430167597765,1842.93611822301,PLAU;CCL2
Pertussis toxin-insensitive CCR5 Signaling in Macrophage Homo sapiens h Ccr5Pathway,1/9,0.00134943189234641,0.002248385285759,0,0,1249.3125,8255.5464452602,CCL2
Platelet Amyloid Precursor Protein Pathway Homo sapiens h plateletAppPathway,1/14,0.00209859705054957,0.002248385285759,0,0,768.615384615385,4739.65618438129,PLAU
Fibrinolysis Pathway Homo sapiens h fibrinolysisPathway,1/15,0.002248385285759,0.002248385285759,0,0,713.678571428571,4351.68575689191,PLAU
Proteins Involved in Atherosclerosis,2/200,0.000296535132839628,0.00247755582409442,0,0,199.989898989899,1624.58691694667,PLAU;CCL2
Proteins Involved in Myocarditis,2/207,0.000317635362063387,0.00247755582409442,0,0,193.092682926829,1555.28557770728,PLAU;CCL2
RET druginhibition 184 GSE49414,2/300,0.000666082804060468,0.00532866243248375,0,0,132.208053691275,966.982471333147,PLAU;CCL2
Vitamin D metabolism and pathway Homo sapiens P04396,1/8,0.00119955410911963,0.00562096321439751,0,0,1427.85714285714,9603.48923469958,CYP27B1
Plasminogen activating cascade Homo sapiens P00050,1/15,0.002248385285759,0.00562096321439751,0,0,713.678571428571,4351.68575689191,PLAU
UrokinaseR -> STAT Signaling,1/7,0.0010496614322995,0.00767564922369008,0,0,1665.91666666667,11427.0015546883,PLAU
ADK Expression Downregulation after Acute Seizures,1/8,0.00119955410911963,0.00825575475099981,0,0,1427.85714285714,9603.48923469958,CCL2
HCC827 Secretory S3 30609389,2/379,0.00106099017834862,0.008487921426789,0,0,104.084880636605,712.830787853366,CYP27B1;PLAU
Beta5 beta6 beta7 and beta8 integrin cell surface interactions Homo sapiens 108637d6-618e-11e5-8ac5-06603eb7f303,1/17,0.00254791692627063,0.00901093861824211,0,0,624.40625,3729.25330632509,PLAU
Beta2 integrin cell surface interactions Homo sapiens 95b6b434-618d-11e5-8ac5-06603eb7f303,1/29,0.00434385079686094,0.00901093861824211,0,0,356.589285714286,1939.48700111416,PLAU
Osteopontin-mediated events Homo sapiens 94bf7f2a-6194-11e5-8ac5-06603eb7f303,1/31,0.00464296371323848,0.00901093861824211,0,0,332.783333333333,1787.84597380293,PLAU
GMCSF-mediated signaling events Homo sapiens 095aa3ef-6193-11e5-8ac5-06603eb7f303,1/36,0.00539048423315445,0.00901093861824211,0,0,285.171428571429,1489.48460880267,CCL2
IL23-mediated signaling events Homo sapiens b71d0ffd-6193-11e5-8ac5-06603eb7f303,1/37,0.00553994346161035,0.00901093861824211,0,0,277.236111111111,1440.45534176172,CCL2
amb2 Integrin signaling Homo sapiens 5d4f90b6-6188-11e5-8ac5-06603eb7f303,1/40,0.0059882314019792,0.00901093861824211,0,0,255.871794871795,1309.5413986235,PLAU
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling Homo sapiens 503076a2-6196-11e5-8ac5-06603eb7f303,1/42,0.00628701524151983,0.00901093861824211,0,0,243.365853658537,1233.6869399593,PLAU
Beta3 integrin cell surface interactions Homo sapiens c2800165-618d-11e5-8ac5-06603eb7f303,1/43,0.00643638472731579,0.00901093861824211,0,0,237.559523809524,1198.67505967293,PLAU
Neuroinflammation in Amyotrophic Lateral Sclerosis,1/10,0.00149929476953185,0.00907107167013115,0,0,1110.44444444444,7220.9541986836,CCL2
Hexosamine Pathway in Diabetic Microangiopathy,1/11,0.00164914273085112,0.00907107167013115,0,0,999.35,6403.33480835207,PLAU
Cochlear Inflammation (Noise-Induced),1/12,0.00179897576875959,0.00907107167013115,0,0,908.454545454545,5741.92128812022,CCL2
Proteins with Altered Expression in Systemic Scleroderma,1/12,0.00179897576875959,0.00907107167013115,0,0,908.454545454545,5741.92128812022,CCL2
Chemokines Signaling in Atherosclerosis,1/13,0.00194879387700138,0.00907107167013115,0,0,832.708333333333,5196.5535115997,CCL2
Mast-Cell Activation without Degranulation through TNFSF8 Signaling,1/13,0.00194879387700138,0.00907107167013115,0,0,832.708333333333,5196.5535115997,CCL2
Proteins Involved in Urolithiasis,1/14,0.00209859705054957,0.00907107167013115,0,0,768.615384615385,4739.65618438129,PLAU
Keep out Signal: LTF Inhibits Neutrophil Recruitment and Inflammation,1/14,0.00209859705054957,0.00907107167013115,0,0,768.615384615385,4739.65618438129,CCL2
TLR7 and TLR9 in Plasmacytoid Dendritic Cell,1/15,0.002248385285759,0.00907107167013115,0,0,713.678571428571,4351.68575689191,CCL2
Vitamin D Represses Transcription,1/15,0.002248385285759,0.00907107167013115,0,0,713.678571428571,4351.68575689191,CYP27B1
NF-kB Signaling Activation in Huntington Disease,1/15,0.002248385285759,0.00907107167013115,0,0,713.678571428571,4351.68575689191,CCL2
Adipose Tissue Inflammation Provokes Insulin Resistance,1/15,0.002248385285759,0.00907107167013115,0,0,713.678571428571,4351.68575689191,CCL2
Fatty Acids in Hypertension and Atherosclerosis Development,1/16,0.00239815857855179,0.00935281845635198,0,0,666.066666666667,4018.41623091548,CCL2
Blood coagulation Homo sapiens P00011,1/38,0.00568938773289464,0.00948231288815774,0,0,269.72972972973,1394.2741447062,PLAU
Genes with Mutations Associated with Systemic Scleroderma,1/17,0.00254791692627063,0.0096163316249569,0,0,624.40625,3729.25330632509,CCL2
Oncostatin M,2/311,0.000715644256726046,0.0098630004527614,0,0,127.430420711974,922.892822752706,PLAU;CCL2
Low-density lipoprotein (LDL) pathway during atherogenesis,1/6,0.000899753878876759,0.0098630004527614,0,0,1999.2,14021.1678884677,CCL2
MSP/RON receptor signaling pathway,1/6,0.000899753878876759,0.0098630004527614,0,0,1999.2,14021.1678884677,CCL2
Cytochrome P450 metabolism of vitamins,1/6,0.000899753878876759,0.0098630004527614,0,0,1999.2,14021.1678884677,CYP27B1
Vitamin D (calciferol) metabolism,1/7,0.0010496614322995,0.0098630004527614,0,0,1665.91666666667,11427.0015546883,CYP27B1
Vitamin D biosynthesis,1/8,0.00119955410911963,0.0098630004527614,0,0,1427.85714285714,9603.48923469958,CYP27B1
Dissolution of fibrin clot,1/8,0.00119955410911963,0.0098630004527614,0,0,1427.85714285714,9603.48923469958,PLAU
Ions Reabsorption Dysregulation in Nephrolithiasis,1/19,0.00284738877757407,0.0101910958013494,0,0,554.972222222222,3252.88805695113,CYP27B1
CCL2 Role in CGRP Expression and Release,1/21,0.00314680082428191,0.0101910958013494,0,0,499.425,2877.37168963486,CCL2
Cyclosporine Induced Nephrotoxicity,1/22,0.003296484417552,0.0101910958013494,0,0,475.619047619048,2718.11467997229,CCL2
Low-Density Lipoproteins and Chemokines in Atherosclerosis,1/22,0.003296484417552,0.0101910958013494,0,0,475.619047619048,2718.11467997229,CCL2
Advanced Glycation End Products Pathway in Diabetic Microangiopathy,1/22,0.003296484417552,0.0101910958013494,0,0,475.619047619048,2718.11467997229,PLAU
HMGB1 and IL1B in Neuroinflammation,1/23,0.00344615305630759,0.0101910958013494,0,0,453.977272727273,2574.27663877793,CCL2
UrokinaseR -> ELK/SRF Signaling,1/23,0.00344615305630759,0.0101910958013494,0,0,453.977272727273,2574.27663877793,PLAU
Microangiopathy in Diabetic Neuropathy,1/24,0.00359580673873441,0.0101910958013494,0,0,434.217391304348,2443.76979314669,CCL2
Blood-Brain Barrier Disruption in Epileptiform Disorders,1/25,0.0037454454654532,0.0101910958013494,0,0,416.104166666667,2324.86332492857,CCL2
MTOR/TORC in Cancer Cell Motility and Invasion,1/25,0.0037454454654532,0.0101910958013494,0,0,416.104166666667,2324.86332492857,PLAU
Endothelial Cell Dysfunction in Early Diabetic Nephropathy,1/25,0.0037454454654532,0.0101910958013494,0,0,416.104166666667,2324.86332492857,CCL2
Lipids Enhance Apoptotic Cell Engulfment and Reduce Inflammation,1/25,0.0037454454654532,0.0101910958013494,0,0,416.104166666667,2324.86332492857,CCL2
ATF-2 transcription factor network Homo sapiens c76c900a-618a-11e5-8ac5-06603eb7f303,1/58,0.00867513250274921,0.0102949731993595,0,0,174.912280701754,830.360139497581,PLAU
FGF signaling pathway Homo sapiens 98ed0df6-6192-11e5-8ac5-06603eb7f303,1/59,0.00882426274230812,0.0102949731993595,0,0,171.887931034483,813.072923866346,PLAU
Beta1 integrin cell surface interactions Homo sapiens 2fd0bc63-618d-11e5-8ac5-06603eb7f303,1/66,0.00986775589382722,0.0106268140395062,0,0,153.323076923077,708.119996336647,PLAU
ROCK2 knockdown 157 GSE34769,2/300,0.000666082804060468,0.0106573248649675,0,0,132.208053691275,966.982471333147,PLAU;CCL2
CCR1 Expression Targets,1/27,0.00404467804622706,0.010755166622922,0,0,384.057692307692,2116.29358166937,CCL2
E2F transcription factor network Homo sapiens bb4d0fd3-6191-11e5-8ac5-06603eb7f303,1/72,0.0107615957524882,0.0107615957524882,0,0,140.323943661972,635.916038987997,PLAU
Vitamins Homo sapiens R-HSA-211916,1/6,0.000899753878876759,0.0110214450391447,0,0,1999.2,14021.1678884677,CYP27B1
Vitamin D (calciferol) metabolism Homo sapiens R-HSA-196791,1/7,0.0010496614322995,0.0110214450391447,0,0,1665.91666666667,11427.0015546883,CYP27B1
Majeed Syndrome,1/29,0.00434385079686094,0.0112940120718384,0,0,356.589285714286,1939.48700111416,CCL2
Vascular Endothelial Cell Activation by NO,1/31,0.00464296371323848,0.0115580160521043,0,0,332.783333333333,1787.84597380293,PLAU
Vitamine D Deficite and Dentin Formation,1/31,0.00464296371323848,0.0115580160521043,0,0,332.783333333333,1787.84597380293,CYP27B1
BL6185 (USP1),1/78,0.0116548977410568,0.0116548977410568,0,0,129.350649350649,575.872813667217,PLAU
Coagulation Factors and PAR1/2 Receptors (F2R/F2RL1) in Endometriosis,1/32,0.00479249773479363,0.011679382505168,0,0,322.032258064516,1719.87882569562,CCL2
Autocrine Cytokine/Chemokine Loops in Systemic Scleroderma,1/33,0.0049420167963793,0.011679382505168,0,0,311.953125,1656.46540769326,CCL2
Proteins Involved in Gout,1/34,0.00509152090098156,0.011679382505168,0,0,302.484848484848,1597.17405140703,PLAU
CCR5 Signaling in Macrophages,1/34,0.00509152090098156,0.011679382505168,0,0,302.484848484848,1597.17405140703,CCL2
N2 Neutrophils in Tumor-Promoting Inflammation and Tumor Progression,1/35,0.00524101004609641,0.011679382505168,0,0,293.573529411765,1541.62536659043,CCL2
Estrogen Effects on Pregnancy Gingivitis,1/36,0.00539048423315445,0.011679382505168,0,0,285.171428571429,1489.48460880267,CCL2
Neutrophil Recruitment in Sinovium in Gout,1/36,0.00539048423315445,0.011679382505168,0,0,285.171428571429,1489.48460880267,CCL2
Osteopontin signaling,1/11,0.00164914273085112,0.0122036562082983,0,0,999.35,6403.33480835207,PLAU
Bradykinin Effects in Inflammation,1/39,0.00583881704612273,0.012420756261752,0,0,262.618421052632,1350.70617046735,PLAU
IL17 Signaling in Psoriasis,1/41,0.00613763080051258,0.0125855500538445,0,0,249.4625,1270.59146099404,CCL2
HIF1A in Vasculogenic Mimicry of Cancer,1/42,0.00628701524151983,0.0125855500538445,0,0,243.365853658537,1233.6869399593,PLAU
Arterial Hypertension,1/44,0.00658573925675946,0.0125855500538445,0,0,232.023255813953,1165.41770566619,CCL2
HIF1A as Master Regulator of Angiogenesis in Cancer,1/44,0.00658573925675946,0.0125855500538445,0,0,232.023255813953,1165.41770566619,CCL2
Adipokines Production by Adipocyte Impaired in Obesity,1/44,0.00658573925675946,0.0125855500538445,0,0,232.023255813953,1165.41770566619,CCL2
Adipokines Production by Adipocyte,1/46,0.00688440344825683,0.0125855500538445,0,0,221.688888888889,1103.67742297314,CCL2
Toll-like Receptors in beta-Cell,1/46,0.00688440344825683,0.0125855500538445,0,0,221.688888888889,1103.67742297314,CCL2
Proteins with Altered Expression in Melanoma,1/46,0.00688440344825683,0.0125855500538445,0,0,221.688888888889,1103.67742297314,PLAU
Peripheral Tissue Microangiopathy,1/46,0.00688440344825683,0.0125855500538445,0,0,221.688888888889,1103.67742297314,PLAU
Keratinocyte Activation in Psoriatic Arthritis,1/47,0.00703371311091952,0.0126606835996551,0,0,216.858695652174,1074.97734402388,CCL2
Proteins Involved in Systemic Scleroderma,1/49,0.00733228757304079,0.0126861105462276,0,0,207.802083333333,1021.44443446465,CCL2
Mast-Cell Activation without Degranulation,1/49,0.00733228757304079,0.0126861105462276,0,0,207.802083333333,1021.44443446465,CCL2
Eosinophil Survival in Asthma,1/50,0.00748155237341628,0.0126861105462276,0,0,203.551020408163,996.446357764973,CCL2
Plasmin Role in Glomerulonephritis,1/50,0.00748155237341628,0.0126861105462276,0,0,203.551020408163,996.446357764973,CCL2
Scavenger Receptor OLR1 in Inflammation Related Endothelial Dysfunction,1/51,0.00763080222089554,0.0127543408549254,0,0,199.47,972.528411753474,CCL2
Proteins Involved in Multiple Sclerosis,1/54,0.008078462047278,0.0133123952046694,0,0,188.150943396226,906.615436737158,CCL2
Endothelial Cell Dysfunction in Glomerulonephritis,1/55,0.00822765208709083,0.0133699346415226,0,0,184.657407407407,886.402567873523,CCL2
beta-Cell Destruction through Cytokines in Diabetes Mellitus,1/57,0.00852598731368867,0.0134802772392105,0,0,178.044642857143,848.317994834409,CCL2
Vascular Endothelial Cell Activation by Blood Coagulation Factors,1/57,0.00852598731368867,0.0134802772392105,0,0,178.044642857143,848.317994834409,CCL2
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma,1/58,0.00867513250274921,0.0135332067042888,0,0,174.912280701754,830.360139497581,CCL2
Proliferative Diabetic Retinopathy,1/60,0.00897337803301339,0.0136348731150983,0,0,168.966101694915,796.42055134622,PLAU
Th2-Cells Function in Systemic Scleroderma,1/60,0.00897337803301339,0.0136348731150983,0,0,168.966101694915,796.42055134622,CCL2
Dissolution of Fibrin Clot Homo sapiens R-HSA-75205,1/13,0.00194879387700138,0.0136415571390096,0,0,832.708333333333,5196.5535115997,PLAU
Platelet amyloid precursor protein pathway,1/14,0.00209859705054957,0.0138650425955139,0,0,768.615384615385,4739.65618438129,PLAU
Fibrinolysis pathway,1/15,0.002248385285759,0.0138650425955139,0,0,713.678571428571,4351.68575689191,PLAU
Integrin beta-5 pathway,1/17,0.00254791692627063,0.0142590617267839,0,0,624.40625,3729.25330632509,PLAU
Pertussis toxin-insensitive CCR5 signaling in macrophage,1/18,0.00269766032668885,0.0142590617267839,0,0,587.647058823529,3476.15003346063,CCL2
Toll-like Receptor Independent Sterile Inflammation,1/66,0.00986775589382722,0.0144315929947223,0,0,153.323076923077,708.119996336647,CCL2
Vascular Endothelial Cell Activation by Cytokines,1/66,0.00986775589382722,0.0144315929947223,0,0,153.323076923077,708.119996336647,CCL2
Proteins Involved in Inflammatory Bowel Diseases,1/66,0.00986775589382722,0.0144315929947223,0,0,153.323076923077,708.119996336647,CCL2
Skin Fibrosis,1/67,0.0100167665600723,0.0144686628089933,0,0,150.992424242424,695.092860072288,CCL2
Cytokines Trigger Otitis Media,1/71,0.0106126597969387,0.0148130200357778,0,0,142.335714285714,647.016548147989,CCL2
Eosinophil Survival by Cytokine Signaling,1/72,0.0107615957524882,0.0148130200357778,0,0,140.323943661972,635.916038987997,CCL2
Proteins Involved in Systemic Lupus Erythematosus,1/72,0.0107615957524882,0.0148130200357778,0,0,140.323943661972,635.916038987997,CCL2
Alveolar Macrophages Dysfunction in COPD,1/72,0.0107615957524882,0.0148130200357778,0,0,140.323943661972,635.916038987997,CCL2
Vaccinia virus Ankara Haemagglutinin,2/446,0.00146653565389414,0.0148653650039599,0,0,88.0765765765766,574.686658325565,PLAU;CCL2
Horsepox virus HSPV177 (Immunoglobulin like),2/538,0.00212814486960497,0.0148653650039599,0,0,72.615671641791,446.768256131769,PLAU;CCL2
Vaccinia virus hemagglutinin (gene: A56R),2/576,0.00243654679991788,0.0148653650039599,0,0,67.6759581881533,407.21798138602,PLAU;CCL2
Horsepox virus HSPV036 (serine protease inhibitor-like protein),1/23,0.00344615305630759,0.0148653650039599,0,0,453.977272727273,2574.27663877793,PLAU
Monkeypox virus Zaire-96-I-16 B2R (gene: B2R),2/702,0.0036047627266627,0.0148653650039599,0,0,55.1342857142857,310.157887249699,PLAU;CCL2
Astrovirus VA1 non-structural protein 1a,1/25,0.0037454454654532,0.0148653650039599,0,0,416.104166666667,2324.86332492857,PLAU
Astrovirus SG nonstructural protein 1a,1/26,0.00389506923436901,0.0148653650039599,0,0,399.44,2216.11062530876,PLAU
Cowpox virus CPXV014 protein (gene: CPXV014 CDS),1/27,0.00404467804622706,0.0148653650039599,0,0,384.057692307692,2116.29358166937,CCL2
Astrovirus SG nonstructural protein 1ab,1/30,0.00449341473423012,0.0148653650039599,0,0,344.275862068966,1860.86004091357,PLAU
Astrovirus VA1 non-structural protein 1ab,1/31,0.00464296371323848,0.0148653650039599,0,0,332.783333333333,1787.84597380293,PLAU
Vaccinia virus Ankara serine protease inhibitor, SPI-3,1/31,0.00464296371323848,0.0148653650039599,0,0,332.783333333333,1787.84597380293,PLAU
Monkeypox virus Zaire-96-I-16 serine protease inhibitor-like protein (gene: C2L),1/31,0.00464296371323848,0.0148653650039599,0,0,332.783333333333,1787.84597380293,PLAU
Ectromelia virus ERPV chemokine binding protein,1/31,0.00464296371323848,0.0148653650039599,0,0,332.783333333333,1787.84597380293,CCL2
Yaba-like disease virus 10L protein (gene: 10L),1/35,0.00524101004609641,0.0148653650039599,0,0,293.573529411765,1541.62536659043,PLAU
Ectromelia virus ERPV serpin,1/36,0.00539048423315445,0.0148653650039599,0,0,285.171428571429,1489.48460880267,PLAU
Vaccinia virus serine protease inhibitor-like protein (gene: K2L),1/37,0.00553994346161035,0.0148653650039599,0,0,277.236111111111,1440.45534176172,PLAU
Horsepox virus HSPV002 (chemokine binding protein; Provisional),1/45,0.00673507883011605,0.0148653650039599,0,0,226.738636363636,1133.78971911263,CCL2
Monkeypox virus chemokine-binding protein,1/46,0.00688440344825683,0.0148653650039599,0,0,221.688888888889,1103.67742297314,CCL2
Monkeypox virus Zaire-96-I-16 chemokine binding protein (gene: J1L),1/47,0.00703371311091952,0.0148653650039599,0,0,216.858695652174,1074.97734402388,CCL2
Cowpox virus CrmD or CPXV221 protein (gene: CrmD),1/48,0.0071830078183245,0.0148653650039599,0,0,212.234042553192,1047.59510101556,CCL2
Variola virus chemokine binding protein (gene: G5R),1/51,0.00763080222089554,0.0148653650039599,0,0,199.47,972.528411753474,CCL2
Variola virus serine protease inhibitor-like protein (gene: C2L),1/52,0.0077800371147531,0.0148653650039599,0,0,195.549019607843,949.624009021504,PLAU
Vaccinia virus Ankara viral chemokine binding protein,1/57,0.00852598731368867,0.0148653650039599,0,0,178.044642857143,848.317994834409,CCL2
Variola virus hypothetical protein (gene: G4R),1/57,0.00852598731368867,0.0148653650039599,0,0,178.044642857143,848.317994834409,CCL2
Horsepox virus HSPV003 (Tumor necrosis factor receptor superfamily members),1/57,0.00852598731368867,0.0148653650039599,0,0,178.044642857143,848.317994834409,CCL2
Ectromelia virus ERPV tumor necrosis factor receptor,1/57,0.00852598731368867,0.0148653650039599,0,0,178.044642857143,848.317994834409,CCL2
Vaccinia virus chemokine binding protein (gene: C23L),1/57,0.00852598731368867,0.0148653650039599,0,0,178.044642857143,848.317994834409,CCL2
Cowpox virus SPI3 or CPXV042 protein (gene: SPI3),1/59,0.00882426274230812,0.0148653650039599,0,0,171.887931034483,813.072923866346,PLAU
Human gammaherpesvirus 8 K6 (gene: K6),1/62,0.00927156377294136,0.0148653650039599,0,0,163.409836065574,764.889287135438,CCL2
Cercopithecine betaherpesvirus 5 chemokine vCXCL9 (gene: UL146F),1/63,0.00942063422116617,0.0148653650039599,0,0,160.766129032258,749.950337703132,CCL2
Monkeypox virus Zaire-96-I-16 J2L (gene: J2L),1/63,0.00942063422116617,0.0148653650039599,0,0,160.766129032258,749.950337703132,CCL2
Cowpox virus CrmB or CPXV005 protein (gene: crmB),1/66,0.00986775589382722,0.0148653650039599,0,0,153.323076923077,708.119996336647,CCL2
Monkeypox virus TNF-alpha-receptor-like protein,1/67,0.0100167665600723,0.0148653650039599,0,0,150.992424242424,695.092860072288,CCL2
Cercopithecine betaherpesvirus 5 chemokine vCXCL5 (gene: UL146B),1/69,0.0103147430639722,0.0148653650039599,0,0,146.536764705882,670.28569103547,CCL2
Human cosavirus D 3C,1/72,0.0107615957524882,0.0150662340534834,0,0,140.323943661972,635.916038987997,PLAU
VEGFA-VEGFR2 Signaling Pathway WP3888,2/432,0.00137646220569506,0.0151023883026845,0,0,91.0093023255814,599.591006783442,PLAU;CCL2
Vitamin D Metabolism WP1531,1/10,0.00149929476953185,0.0151023883026845,0,0,1110.44444444444,7220.9541986836,CYP27B1
Osteopontin Signaling WP1434,1/13,0.00194879387700138,0.0151023883026845,0,0,832.708333333333,5196.5535115997,PLAU
COVID-19 adverse outcome pathway WP4891,1/15,0.002248385285759,0.0151023883026845,0,0,713.678571428571,4351.68575689191,CCL2
Platelet-mediated interactions with vascular and circulating cells WP4462,1/17,0.00254791692627063,0.0151023883026845,0,0,624.40625,3729.25330632509,CCL2
FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,1/22,0.003296484417552,0.0151023883026845,0,0,475.619047619048,2718.11467997229,CYP27B1
Blood Clotting Cascade WP272,1/23,0.00344615305630759,0.0151023883026845,0,0,453.977272727273,2574.27663877793,PLAU
IL1 and megakaryocytes in obesity WP2865,1/24,0.00359580673873441,0.0151023883026845,0,0,434.217391304348,2443.76979314669,CCL2
Glioma Invasion Signaling,1/75,0.0112083139716832,0.0152485201707783,0,0,134.614864864865,604.568746520693,PLAU
Mast-Cell Activation in Asthma,1/76,0.0113571901659932,0.0152734626370254,0,0,132.813333333333,594.725388571662,CCL2
Blood clotting cascade,1/23,0.00344615305630759,0.0153069028079862,0,0,453.977272727273,2574.27663877793,PLAU
Steroid biosynthesis,1/26,0.00389506923436901,0.0153069028079862,0,0,399.44,2216.11062530876,CYP27B1
Fibroblast growth factor 1,1/26,0.00389506923436901,0.0153069028079862,0,0,399.44,2216.11062530876,PLAU
Interleukin-9 regulation of target genes,1/26,0.00389506923436901,0.0153069028079862,0,0,399.44,2216.11062530876,CCL2
TWEAK regulation of gene expression,1/27,0.00404467804622706,0.0153069028079862,0,0,384.057692307692,2116.29358166937,CCL2
PERK-regulated gene expression,1/28,0.00419427190091997,0.0153069028079862,0,0,369.814814814815,2024.37943125831,CCL2
Integrin beta-2 pathway,1/29,0.00434385079686094,0.0153069028079862,0,0,356.589285714286,1939.48700111416,PLAU
Alpha-V beta-3 integrin/OPN pathway,1/31,0.00464296371323848,0.0156172415808931,0,0,332.783333333333,1787.84597380293,PLAU
Proplatelet Maturation,1/79,0.0118037291244742,0.0156935944041304,0,0,127.685897435897,566.841082547516,CCL2
Nuclear receptors in lipid metabolism and toxicity,1/34,0.00509152090098156,0.0157675313907371,0,0,302.484848484848,1597.17405140703,CYP27B1
GM-CSF-mediated signaling events,1/36,0.00539048423315445,0.0157675313907371,0,0,285.171428571429,1489.48460880267,CCL2
Steroid hormone, vitamin A, and vitamin D metabolism,1/36,0.00539048423315445,0.0157675313907371,0,0,285.171428571429,1489.48460880267,CYP27B1
Interleukin-23-mediated signaling events,1/37,0.00553994346161035,0.0157675313907371,0,0,277.236111111111,1440.45534176172,CCL2
Alpha-M beta-2 integrin signaling,1/41,0.00613763080051258,0.0158764156607123,0,0,249.4625,1270.59146099404,PLAU
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,1/42,0.00628701524151983,0.0158764156607123,0,0,243.365853658537,1233.6869399593,PLAU
TWEAK signaling pathway,1/42,0.00628701524151983,0.0158764156607123,0,0,243.365853658537,1233.6869399593,CCL2
Beta-3 integrin cell surface interactions,1/43,0.00643638472731579,0.0158764156607123,0,0,237.559523809524,1198.67505967293,PLAU
Proteins Involved in Insulin Resistance,1/81,0.012101347079867,0.0159085124533083,0,0,124.48125,549.514822983903,CCL2
Interactions between immune cells and microRNAs in tumor microenvironment WP4559,1/28,0.00419427190091997,0.0160144927126035,0,0,369.814814814815,2024.37943125831,CCL2
Nuclear Receptors in Lipid Metabolism and Toxicity WP299,1/33,0.0049420167963793,0.0162768805132773,0,0,311.953125,1656.46540769326,CYP27B1
Vitamin D-sensitive calcium signaling in depression WP4698,1/41,0.00613763080051258,0.0162768805132773,0,0,249.4625,1270.59146099404,CYP27B1
Fibrin Complement Receptor 3 Signaling Pathway WP4136,1/41,0.00613763080051258,0.0162768805132773,0,0,249.4625,1270.59146099404,CCL2
TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,1/42,0.00628701524151983,0.0162768805132773,0,0,243.365853658537,1233.6869399593,CCL2
Vitamin B12 metabolism WP1533,1/50,0.00748155237341628,0.0162768805132773,0,0,203.551020408163,996.446357764973,CCL2
Netrin-UNC5B signaling pathway WP4747,1/52,0.0077800371147531,0.0162768805132773,0,0,195.549019607843,949.624009021504,CCL2
IL-1 signaling pathway WP195,1/55,0.00822765208709083,0.0162768805132773,0,0,184.657407407407,886.402567873523,CCL2
Complement and Coagulation Cascades WP558,1/58,0.00867513250274921,0.0162768805132773,0,0,174.912280701754,830.360139497581,PLAU
Oxidation by Cytochrome P450 WP43,1/61,0.00912247837612096,0.0162768805132773,0,0,166.141666666667,780.369694450321,CYP27B1
Endochondral Ossification with Skeletal Dysplasias WP4808,1/64,0.00956968972447913,0.0162768805132773,0,0,158.206349206349,735.525759665316,PLAU
Endochondral Ossification WP474,1/64,0.00956968972447913,0.0162768805132773,0,0,158.206349206349,735.525759665316,PLAU
Oncostatin M Signaling Pathway WP2374,1/65,0.00971873028148459,0.0162768805132773,0,0,155.7265625,721.590219143659,CCL2
SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,1/66,0.00986775589382722,0.0162768805132773,0,0,153.323076923077,708.119996336647,CCL2
p53 transcriptional gene network WP4963,1/67,0.0100167665600723,0.0162768805132773,0,0,150.992424242424,695.092860072288,CCL2
Folate Metabolism WP176,1/69,0.0103147430639722,0.0162768805132773,0,0,146.536764705882,670.28569103547,CCL2
Glucocorticoid Receptor Pathway WP2880,1/70,0.0104637089013926,0.0162768805132773,0,0,144.405797101449,658.467662524263,CCL2
Proteins Involved in Glaucoma,1/84,0.0125476620021733,0.0163119606028253,0,0,119.963855421687,525.228262099716,CCL2
Proteins Involved in Osteoarthritis,1/86,0.012845130618796,0.0163356552434689,0,0,117.129411764706,510.074047237415,PLAU
Mast-Cell Activation via IgE Signaling,1/86,0.012845130618796,0.0163356552434689,0,0,117.129411764706,510.074047237415,CCL2
CC Chemokine Receptor Signaling,1/88,0.0131425395073887,0.0165341626060696,0,0,114.425287356322,495.679018920707,CCL2
ATF4 activates genes Homo sapiens R-HSA-380994,1/25,0.0037454454654532,0.0176159419838639,0,0,416.104166666667,2324.86332492857,CCL2
PERK regulates gene expression Homo sapiens R-HSA-381042,1/28,0.00419427190091997,0.0176159419838639,0,0,369.814814814815,2024.37943125831,CCL2
Malaria,1/51,0.00763080222089554,0.0177648263113934,0,0,199.47,972.528411753474,CCL2
Vitamin B12 metabolism,1/52,0.0077800371147531,0.0177648263113934,0,0,195.549019607843,949.624009021504,CCL2
Binding of chemokines to chemokine receptors,1/54,0.008078462047278,0.0177648263113934,0,0,188.150943396226,906.615436737158,CCL2
ATF2 transcription factor network,1/59,0.00882426274230812,0.0177648263113934,0,0,171.887931034483,813.072923866346,PLAU
Selenium pathway,1/60,0.00897337803301339,0.0177648263113934,0,0,168.966101694915,796.42055134622,CCL2
RAGE pathway,1/60,0.00897337803301339,0.0177648263113934,0,0,168.966101694915,796.42055134622,CCL2
FGF signaling pathway,1/61,0.00912247837612096,0.0177648263113934,0,0,166.141666666667,780.369694450321,PLAU
Cytochrome P450 pathway,1/61,0.00912247837612096,0.0177648263113934,0,0,166.141666666667,780.369694450321,CYP27B1
Folate metabolism,1/63,0.00942063422116617,0.017810096003493,0,0,160.766129032258,749.950337703132,CCL2
Endochondral ossification,1/66,0.00986775589382722,0.017810096003493,0,0,153.323076923077,708.119996336647,PLAU
Beta-1 integrin cell surface interactions,1/66,0.00986775589382722,0.017810096003493,0,0,153.323076923077,708.119996336647,PLAU
Proteins Involved in Rheumatoid Arthritis,1/96,0.0143315779013053,0.0178334362332216,0,0,104.747368421053,444.682948504716,CCL2
Proteins Involved in Polycystic Kidney Disease,1/97,0.0144801405312483,0.0178334362332216,0,0,103.651041666667,438.959796854159,CCL2
Phase I of biological oxidations: functionalization of compounds,1/69,0.0103147430639722,0.0180073129930942,0,0,146.536764705882,670.28569103547,CYP27B1
Complement and coagulation cascades,1/70,0.0104637089013926,0.0180073129930942,0,0,144.405797101449,658.467662524263,PLAU
Proteins Involved in Polycystic Ovary Syndrome,1/99,0.0147772210176025,0.0180097381152031,0,0,101.525510204082,427.896360088283,CCL2
E2F transcription factor network,1/74,0.0110594228380556,0.0181866064448026,0,0,136.465753424658,614.706229245501,PLAU
RANKL regulation of apoptosis and immune response,1/74,0.0110594228380556,0.0181866064448026,0,0,136.465753424658,614.706229245501,CCL2
Proteins Involved in Obesity,1/106,0.0158165326939135,0.0188830033182437,0,0,94.7238095238095,392.791174820312,CCL2
Proteins with Altered Expression in Cancer Metastases,1/106,0.0158165326939135,0.0188830033182437,0,0,94.7238095238095,392.791174820312,PLAU
Unfolded protein response,1/79,0.0118037291244742,0.0189886077219802,0,0,127.685897435897,566.841082547516,CCL2
ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,1/86,0.012845130618796,0.0190143590461056,0,0,117.129411764706,510.074047237415,PLAU
Selenium Micronutrient Network WP15,1/89,0.0132912215554317,0.0190143590461056,0,0,113.119318181818,488.749151226804,CCL2
TNF-alpha signaling pathway WP231,1/92,0.0137371781268084,0.0190143590461056,0,0,109.373626373626,468.955762379618,CCL2
LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,1/94,0.0140344078673636,0.0190143590461056,0,0,107.010752688172,456.533902379078,PLAU
ATM-dependent DNA damage response,1/82,0.012250133655514,0.0192874444788944,0,0,122.938271604938,541.201125183315,PLAU
Steroid hormones Homo sapiens R-HSA-209943,1/37,0.00553994346161035,0.0193898021156362,0,0,277.236111111111,1440.45534176172,CYP27B1
Cercopithecine betaherpesvirus 5 chemokine vCXCL10 (gene: UL146G),1/96,0.0143315779013053,0.0195068699212211,0,0,104.747368421053,444.682948504716,CCL2
NOD signaling pathway,1/85,0.0126964037761181,0.0195736224881821,0,0,118.529761904762,517.552677869987,CCL2
Wnt signaling pathway and pluripotency WP399,1/102,0.0152227298331673,0.019941223726086,0,0,98.4950495049505,412.198392406259,PLAU
Senescence and Autophagy in Cancer WP615,1/105,0.0156681043562104,0.019941223726086,0,0,95.6394230769231,397.489703543101,PLAU
Human rhinovirus B17 full_polyprotein 1..2186,1/102,0.0152227298331673,0.0201598314006811,0,0,98.4950495049505,412.198392406259,PLAU
Proteins Involved in Diabetes Mellitus Type 2,1/115,0.0171517164979722,0.0202702104066944,0,0,87.2061403508772,354.55025696917,CCL2
DNA damage response (only ATM dependent) WP710,1/110,0.0164100968682601,0.0202712961313802,0,0,91.2293577981651,374.939748941166,PLAU
Thymic stromal lymphopoietin (TSLP) pathway,1/90,0.0134398886742326,0.0202969747325145,0,0,111.842696629213,481.989258117309,CCL2
Wnt signaling WP428,1/115,0.0171517164979722,0.0205292608869433,0,0,87.2061403508772,354.55025696917,PLAU
Spinal Cord Injury WP2431,1/118,0.0175965093316657,0.0205292608869433,0,0,84.957264957265,343.232000141587,CCL2
Proteins Involved in Glomerulonephritis,1/121,0.0180411679776536,0.0211081665338547,0,0,82.8208333333333,332.533846973471,CCL2
TSH regulation of gene expression,1/97,0.0144801405312483,0.0212259397957839,0,0,103.651041666667,438.959796854159,CCL2
Wnt signaling pathway and pluripotency,1/98,0.0146286882376348,0.0212259397957839,0,0,102.577319587629,433.365657403815,PLAU
Receptors and Adaptor Proteins Activated in Cancer,1/125,0.0186338374756652,0.0215857325213152,0,0,80.133064516129,319.152056732132,PLAU
Metabolism of fat-soluble vitamins Homo sapiens R-HSA-6806667,1/51,0.00763080222089554,0.0216336488035298,0,0,199.47,972.528411753474,CYP27B1
Chemokine receptors bind chemokines Homo sapiens R-HSA-380108,1/56,0.00837682717621764,0.0216336488035298,0,0,181.290909090909,866.9849864024,CCL2
Cytochrome P450 - arranged by substrate type Homo sapiens R-HSA-211897,1/62,0.00927156377294136,0.0216336488035298,0,0,163.409836065574,764.889287135438,CYP27B1
Chagas disease,1/104,0.0155196611008772,0.0220856715666329,0,0,96.5728155339806,402.288317326718,CCL2
Proteins Involved in Alzheimer's Disease,1/130,0.0193743389965825,0.02222350649608,0,0,77.0077519379845,303.703620326663,CCL2
Vaccinia virus Ankara serine proteinase inhibitor / SPI-2 f2,1/118,0.0175965093316657,0.0226902357171478,0,0,84.957264957265,343.232000141587,PLAU
Leptin influence on immune response,1/110,0.0164100968682601,0.0229122107217217,0,0,91.2293577981651,374.939748941166,CCL2
Human betaherpesvirus 5 chemokine vCXCL1 (gene: UL146),1/127,0.0189300827920364,0.0231893514202445,0,0,78.8531746031746,312.810775493451,CCL2
Cercopithecine betaherpesvirus 5 chemokine vCXCL2 (gene: UL147),1/127,0.0189300827920364,0.0231893514202445,0,0,78.8531746031746,312.810775493451,CCL2
Human betaherpesvirus 5 chemokine vCXCL2 (gene: UL147),1/131,0.0195223945937551,0.0233316423193659,0,0,76.4115384615385,300.770565230774,CCL2
Ectoderm Differentiation WP2858,1/138,0.0205583666198837,0.0233365242712193,0,0,72.4817518248175,281.554443438429,CCL2
Human gammaherpesvirus 8 K4.1 (gene: K4.1),1/137,0.020410415306419,0.0238121511908222,0,0,73.0183823529412,284.16636544137,CCL2
Molluscum contagiosum virus subtype 1 MC148R (gene: MC148R),1/141,0.0210021311855888,0.0239326611184617,0,0,70.9178571428571,273.964998010433,CCL2
Nociception Expression Targets Signaling,1/143,0.0212978997651538,0.0241927599274077,0,0,69.9119718309859,269.101443612951,CCL2
Melanoma,1/145,0.0215936087756324,0.0242928098725864,0,0,68.9340277777778,264.386667884871,PLAU
Interleukin-1 regulation of extracellular matrix,1/120,0.0178929633377612,0.0245199867961913,0,0,83.5210084033613,336.034061491762,CCL2
Proteins Involved in Age-Related Macular Degeneration,1/148,0.0220370606188443,0.0245555818324265,0,0,67.5170068027211,257.579384137587,CCL2
Interleukin-1 signaling pathway,1/125,0.0186338374756652,0.0250709813308951,0,0,80.133064516129,319.152056732132,CCL2
Nonalcoholic fatty liver disease WP4396,1/155,0.0230712605438279,0.0254998142852835,0,0,64.4253246753247,242.829844345449,CCL2
Unfolded Protein Response (UPR) Homo sapiens R-HSA-381119,1/86,0.012845130618796,0.0262255218784523,0,0,117.129411764706,510.074047237415,CCL2
Phase 1 - Functionalization of compounds Homo sapiens R-HSA-211945,1/92,0.0137371781268084,0.0262255218784523,0,0,109.373626373626,468.955762379618,CYP27B1
TNF-alpha effects on cytokine activity, cell motility, and apoptosis,1/135,0.0201144679925479,0.0264183866317787,0,0,74.115671641791,289.519228220732,CCL2
Diabetes pathways,1/137,0.020410415306419,0.0264183866317787,0,0,73.0183823529412,284.16636544137,CCL2
Biological oxidations,1/139,0.0207063030357184,0.0264183866317787,0,0,71.9528985507246,278.98420614566,CYP27B1
Interleukin-5 regulation of apoptosis,1/144,0.0214457617145024,0.0268980740147996,0,0,69.4195804195804,266.725872449709,CCL2
Proteins Involved in Dilated Cardiomyopathy,1/167,0.0248424781883714,0.0274204712079194,0,0,59.7319277108434,220.72143485852,CCL2
Proteins Involved in Chronic Obstructive Pulmonary Disease,1/170,0.0252849478802057,0.0276480271213464,0,0,58.6627218934911,215.734858585558,CCL2
EGFR1 pathway,1/152,0.0226281213168788,0.0279080162908172,0,0,65.7152317880795,248.966219469226,PLAU
Proteins Involved in Diabetic Nephropathy,1/175,0.0260220999459419,0.0279319788410569,0,0,56.9626436781609,207.845812845536,CCL2
Proteins with Altered Expression in Cancer-Associated Sustaining of Proliferative Signaling,1/175,0.0260220999459419,0.0279319788410569,0,0,56.9626436781609,207.845812845536,PLAU
CCKR signaling map ST Homo sapiens P06959,1/165,0.024547424021947,0.0279369559473935,0,0,60.4664634146341,224.158150565852,PLAU
Inflammation mediated by chemokine and cytokine signaling pathway Homo sapiens P00031,1/188,0.0279369559473935,0.0279369559473935,0,0,52.9679144385027,189.508862799463,CCL2
Proteins Involved in Glioblastoma,1/178,0.0264642127545926,0.0281482990207939,0,0,55.9887005649718,203.348828445737,PLAU
Vitamin D Receptor Pathway WP2877,1/182,0.0270534883841025,0.0285608086348859,0,0,54.7403314917127,197.609275118901,CYP27B1
Metapathway biotransformation Phase I and II WP702,1/183,0.0272007701284628,0.0285608086348859,0,0,54.4368131868132,196.218037093606,CYP27B1
Proteins Involved in non-Alcoholic Fatty Liver Disease,1/186,0.0276425262010214,0.029136716806482,0,0,53.5459459459459,192.144266418974,CCL2
Unfolded Protein Response,1/113,0.0168551133866342,0.0297022864925554,0,0,88.7723214285714,362.466372430338,CCL2
Coagulation,1/138,0.0205583666198837,0.0297022864925554,0,0,72.4817518248175,281.554443438429,PLAU
KRAS Signaling Up,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,PLAU
Interferon Gamma Response,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,CCL2
Allograft Rejection,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,CCL2
Inflammatory Response,1/200,0.0297022864925554,0.0297022864925554,0,0,49.7437185929648,174.925340916176,CCL2
Metapathway biotransformation,1/174,0.0258746992707548,0.0313889794432108,0,0,57.2947976878613,209.383245140563,CYP27B1
MCM2,1/129,0.0192262684961311,0.0326121614175587,0,0,77.61328125,306.68715661621,CCL2
PCNA,1/146,0.0217414409450392,0.0326121614175587,0,0,68.4551724137931,262.083031640473,CCL2
Proteins Involved in Neuroblastoma,1/216,0.0320527344060855,0.0334836600492144,0,0,46.0046511627907,158.273149722992,CCL2
Chemokine signaling pathway,1/189,0.0280841485296891,0.0335063039375535,0,0,52.6835106382979,188.214474407015,CCL2
Peptide G-protein coupled receptors,1/192,0.0285256371360253,0.0335063039375535,0,0,51.848167539267,184.421445684106,CCL2
Steroid biosynthesis,1/20,0.00299710227697048,0.0361980438307643,0,0,525.736842105263,3054.58854972563,CYP27B1
Malaria,1/50,0.00748155237341628,0.0361980438307643,0,0,203.551020408163,996.446357764973,CCL2
Complement and coagulation cascades,1/85,0.0126964037761181,0.0361980438307643,0,0,118.529761904762,517.552677869987,PLAU
Rheumatoid arthritis,1/93,0.013885800458941,0.0361980438307643,0,0,108.179347826087,462.671009812356,CCL2
IL-17 signaling pathway,1/94,0.0140344078673636,0.0361980438307643,0,0,107.010752688172,456.533902379078,CCL2
Prostate cancer,1/97,0.0144801405312483,0.0361980438307643,0,0,103.651041666667,438.959796854159,PLAU
AGE-RAGE signaling pathway in diabetic complications,1/100,0.0149257388776811,0.0361980438307643,0,0,100.494949494949,422.54790984855,CCL2
Viral protein interaction with cytokine and cytokine receptor,1/100,0.0149257388776811,0.0361980438307643,0,0,100.494949494949,422.54790984855,CCL2
Chagas disease,1/102,0.0152227298331673,0.0361980438307643,0,0,98.4950495049505,412.198392406259,CCL2
NF-kappa B signaling pathway,1/104,0.0155196611008772,0.0361980438307643,0,0,96.5728155339806,402.288317326718,PLAU
Parathyroid hormone synthesis, secretion and action,1/106,0.0158165326939135,0.0361980438307643,0,0,94.7238095238095,392.791174820312,CYP27B1
TNF signaling pathway,1/112,0.0167067894603528,0.0361980438307643,0,0,89.5765765765766,366.541984609772,CCL2
Proteins Involved in Melanoma,1/238,0.0352783986095116,0.0365271914806448,0,0,41.6877637130802,139.424077066813,PLAU
Proteins Involved in Myocardial Ischemia,1/252,0.0373273584359295,0.0382390719072406,0,0,39.3346613545817,129.333497446993,CCL2
Proteins Involved in Arterial Hypertension,1/255,0.0377660434991456,0.0382390719072406,0,0,38.8641732283465,127.332435757818,CCL2
Proteins Involved in Endometriosis,1/256,0.0379122422328197,0.0382390719072406,0,0,38.7098039215686,126.677105782298,CCL2
Yersinia infection,1/137,0.020410415306419,0.03845456278062,0,0,73.0183823529412,284.16636544137,CCL2
Fluid shear stress and atherosclerosis,1/139,0.0207063030357184,0.03845456278062,0,0,71.9528985507246,278.98420614566,CCL2
Metabolism of vitamins and cofactors Homo sapiens R-HSA-196854,1/148,0.0220370606188443,0.0385648560829775,0,0,67.5170068027211,257.579384137587,CYP27B1
Influenza A,1/172,0.0255798533173424,0.0388862599260917,0,0,57.9707602339181,212.517921066091,CCL2
Tuberculosis,1/180,0.026758880297526,0.0388862599260917,0,0,55.3575418994413,200.443508274877,CYP27B1
NOD-like receptor signaling pathway,1/181,0.0269061917729785,0.0388862599260917,0,0,55.0472222222222,199.017663445995,CCL2
Transcriptional misregulation in cancer,1/192,0.0285256371360253,0.0388862599260917,0,0,51.848167539267,184.421445684106,PLAU
Chemokine signaling pathway,1/192,0.0285256371360253,0.0388862599260917,0,0,51.848167539267,184.421445684106,CCL2
Proteoglycans in cancer,1/205,0.0304372096910159,0.0388862599260917,0,0,48.5122549019608,169.409131892196,PLAU
Lipid and atherosclerosis,1/215,0.0319059427279597,0.0388862599260917,0,0,46.2219626168224,159.232950730971,CCL2
Human cytomegalovirus infection,1/225,0.0333731918834938,0.0388862599260917,0,0,44.1361607142857,150.063049685329,CCL2
Coronavirus disease,1/232,0.0343993837807734,0.0388862599260917,0,0,42.7835497835498,144.168439115321,CCL2
Wnt signaling pathway,1/231,0.0342528294224071,0.0396048340196582,0,0,42.9717391304348,144.986050811671,PLAU
Proteins Involved in Epilepsy,1/270,0.0399574699889903,0.0399574699889903,0,0,36.6691449814126,118.07243351971,CCL2
IL-18 signaling pathway WP4754,1/272,0.0402494085641292,0.0412311014559372,0,0,36.3948339483395,116.924226114584,CCL2
Ectromelia virus ERPV hemagglutinin,1/262,0.0387891236974251,0.0431969786630416,0,0,37.8084291187739,122.862853087915,CCL2
EPHA2 human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,PLAU
PLK3 human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
DAPK1 human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
CSF1R human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
MERTK human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
CAMK1 human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
SRC human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
IRAK2 human kinase ARCHS4 coexpression,1/299,0.0441847889936254,0.0441847889936254,0,0,33.0520134228188,103.101614109613,CCL2
Cytokine-cytokine receptor interaction,1/265,0.039227364566833,0.0443096876334618,0,0,37.3731060606061,121.028345367316,CCL2
Interleukin-4 regulation of apoptosis,1/267,0.039519451132547,0.0443096876334618,0,0,37.0883458646617,119.83104705578,CCL2
BRD4 druginhibition 224 GSE50865,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
SYK druginhibition 155 GSE34176,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
MAP2K4 knockdown 62 GSE19091,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
CSF1R druginhibition 195 GSE57686,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PDK1 knockout 265 GSE42187,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
EGFR drugactivation 30 GDS4361,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
EPHA4 drugactivation 229 GSE26523,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
ERBB2 druginhibition 7 GDS2139,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
SYK druginhibition 153 GSE34176,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
SYK druginhibition 155 GSE34176,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
ROCK1 knockdown 156 GSE34769,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
RAF1 activemutant 219 GSE42964,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
TBK1 druginhibition 188 GSE53658,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
AKT1 knockout 214 GSE39699,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
FGFR1 mutant 26 GDS4046,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
LRRK2 activemutant 159 GSE36321,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
LRRK2 mutant 33 GDS4401,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
SYK knockdown 279 GDS3609,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
CDK8 knockdown 163 GSE38061,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
TIE1 knockdown 107 GSE27869,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
MAPK1 knockdown 131 GSE31534,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
JAK2 knockdown 192 GSE54645,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
ERBB3 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR34 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR37 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
LGR4 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
MAP3K5 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
QRFPR knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
F2RL1 knockdown 96h HCC515,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
TNIK knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
OPN5 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PDK2 knockdown 96h A549,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
OR52B2 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
GPRC6A knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
OXER1 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
VIPR1 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
P2RY8 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
RPS6KA2 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
ROCK1 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
GPR110 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
RPS6KA3 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
ABCF1 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
VN1R4 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
OXGR1 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
RXFP1 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
PDPK1 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
GPR115 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PHKG2 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
PLK4 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
TAAR1 knockdown 96h A549,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
NMUR2 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
LGR5 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
AURKA knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR158 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
NPSR1 knockdown 96h HA1E,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
PRKCE knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
EPHB2 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
NR1H2 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
LPAR6 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
LGR4 knockdown 96h HCC515,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
LPAR5 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR26 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
LYN knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
TAOK3 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR61 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
FES knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR65 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
CDK5 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
MRGPRX4 knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
MAP4K3 knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
TRIB3 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
SNRK knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
UTS2R knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GABRA5 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GABRP knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
IKBKB knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
CSK knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
IRAK4 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PAK2 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
KCNN4 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PRKAA1 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
STK38L knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
EMR1 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
NPFFR2 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
AXL knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
STK36 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
BTK knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
KISS1R knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
TEK knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PPARA knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR62 knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
FGFR2 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
LPAR5 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GPR84 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
RARG knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
GSK3B knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
CFTR knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
HCAR1 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
HNF4G knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
LPAR3 knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
CHUK knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
MASTL knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
ABL2 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
FZD7 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PIK3CA knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
AGTR1 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
FFAR1 knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
ADRA2A knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
ANO1 knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PTGFR knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
DAPK3 knockdown 96h MCF7,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
SLK knockdown 96h HT29,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
PRKACA knockdown 96h HEPG2,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
RXFP1 knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CCL2
FZD8 knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
GABBR1 knockdown 96h A375,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,CYP27B1
BCKDK knockdown 96h PC3,1/300,0.0443303368659728,0.0443303368659728,0,0,32.9397993311037,102.643248566252,PLAU
Peptide ligand-binding receptors Homo sapiens R-HSA-375276,1/193,0.0286727702925846,0.0443328859548786,0,0,51.5755208333333,183.186315362117,CCL2
Biological oxidations Homo sapiens R-HSA-211859,1/199,0.0295552573032524,0.0443328859548786,0,0,49.9974747474747,176.065789280842,CYP27B1
Nuclear Receptors Meta-Pathway WP2882,1/319,0.0470929399140463,0.0470929399140463,0,0,30.9418238993711,94.546832965283,CCL2
Cytokine-cytokine receptor interaction,1/295,0.0436024497354741,0.0472359872134302,0,0,33.5085034013605,104.970143222771,CCL2
MicroRNAs in cancer,1/310,0.0457850030466385,0.047616403168504,0,0,31.8576051779935,98.2424409831854,PLAU
